{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:20:18Z","timestamp":1762917618450},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.reuma.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T12:53:27Z","timestamp":1439556807000},"page":"91-99","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Los inhibidores de las prote\u00ednas-cinasas en enfermedades autoinmunes e inflamatorias: presente y futuro de nuevas dianas terap\u00e9uticas"],"prefix":"10.1016","volume":"12","author":[{"given":"Diana","family":"Hern\u00e1ndez-Fl\u00f3rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Valor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2015.06.004_bib0365","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: Current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12248","article-title":"Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases","volume":"176","author":"Patterson","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0375","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science."},{"key":"10.1016\/j.reuma.2015.06.004_bib0380","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jprot.2012.10.015","article-title":"Profiling the kinome: Current capabilities and future challenges","volume":"81","author":"Knight","year":"2013","journal-title":"J Proteomics."},{"key":"10.1016\/j.reuma.2015.06.004_bib0385","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrd2871","article-title":"Factors underlying sensitivity of cancers to small-molecule kinase inhibitors","volume":"8","author":"Janne","year":"2009","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.reuma.2015.06.004_bib0390","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2012-4085","article-title":"Clinical review: Kinase inhibitors: adverse effects related to the endocrine system","volume":"98","author":"Lodish","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"10.1016\/j.reuma.2015.06.004_bib0395","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell."},{"key":"10.1016\/j.reuma.2015.06.004_bib0400","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1128\/MMBR.68.2.320-344.2004","article-title":"ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions","volume":"68","author":"Roux","year":"2004","journal-title":"Microbiol Mol Biol Rev."},{"key":"10.1016\/j.reuma.2015.06.004_bib0405","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/ker192","article-title":"New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors","volume":"50","author":"Bonilla-Hern\u00e1n","year":"2011","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.004_bib0410","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bcpt.12141","article-title":"Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target","volume":"114","author":"Korhonen","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0415","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.177.11.7497","article-title":"DUSP meet immunology: Dual specificity MAPK phosphatases in control of the inflammatory response","volume":"177","author":"Lang","year":"2006","journal-title":"J Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0420","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/art.30375","article-title":"Tyr323-dependent p38 activation is associated with rheumatoid arthritis and correlates with disease activity","volume":"63","author":"L\u00f3pez-Santalla","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.004_bib0425","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.drudis.2010.05.001","article-title":"Spleen tyrosine kinases: Biology, therapeutic targets and drugs","volume":"15","author":"Riccaboni","year":"2010","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.reuma.2015.06.004_bib0430","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nri3487","article-title":"New insights into pre-BCR and BCR signalling with relevance to B cell malignancies","volume":"13","author":"Rickert","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0435","doi-asserted-by":"crossref","first-page":"i77","DOI":"10.1136\/ard.2009.119479","article-title":"Go upstream, young man: Lessons learned from the p38 saga","volume":"69","author":"Hammaker","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.06.004_bib0440","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0161-5890(02)00068-8","article-title":"Protein tyrosine kinase Syk in mast cell signaling","volume":"38","author":"Siraganian","year":"2002","journal-title":"Mol Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0445","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene."},{"key":"10.1016\/j.reuma.2015.06.004_bib0450","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pharmthera.2013.02.001","article-title":"Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: Recent progress and therapeutic perspectives","volume":"138","author":"Tan","year":"2013","journal-title":"Pharmacol Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0455","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1124\/pr.110.004051","article-title":"Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory\/autoimmune diseases and hematological malignancies","volume":"64","author":"Foster","year":"2012","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.reuma.2015.06.004_bib0460","doi-asserted-by":"crossref","first-page":"14123","DOI":"10.18632\/oncotarget.4234","article-title":"NF-\u03baB, p38 MAPK, ERK1\/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol\/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment","volume":"6","author":"D\u00e1\u0148ov\u00e1","year":"2015","journal-title":"Oncotarget."},{"key":"10.1016\/j.reuma.2015.06.004_bib0465","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/BJ20112092","article-title":"PI3K signalling in B- and T-lymphocytes: New developments and therapeutic advances","volume":"442","author":"So","year":"2012","journal-title":"Biochem J."},{"key":"10.1016\/j.reuma.2015.06.004_bib0470","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/08830185.2013.818140","article-title":"B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies","volume":"32","author":"Puri","year":"2013","journal-title":"Int Rev Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0475","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.2165\/11591480-000000000-00000","article-title":"Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis","volume":"71","author":"Scott","year":"2011","journal-title":"Drugs."},{"key":"10.1016\/j.reuma.2015.06.004_bib0480","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/sji.12069","article-title":"Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases","volume":"78","author":"Vargas","year":"2013","journal-title":"Scand J Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0485","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: From interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem."},{"key":"10.1016\/j.reuma.2015.06.004_bib0490","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"10.1016\/j.reuma.2015.06.004_bib0495","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/08977194.2012.660936","article-title":"Biology and significance of the JAK\/STAT signalling pathways","volume":"30","author":"Kiu","year":"2012","journal-title":"Growth Factors."},{"key":"10.1016\/j.reuma.2015.06.004_bib0500","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity."},{"key":"10.1016\/j.reuma.2015.06.004_bib0505","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2008.08.014","article-title":"Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates","volume":"14","author":"Kotecha","year":"2008","journal-title":"Cancer Cell."},{"key":"10.1016\/j.reuma.2015.06.004_bib0510","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0515","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.cr.7310027","article-title":"Regulation of cytokine signaling pathways by PIAS proteins","volume":"16","author":"Shuai","year":"2006","journal-title":"Cell Res."},{"key":"10.1016\/j.reuma.2015.06.004_bib0520","series-title":"International Nonproprietary Names (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb). Meeting Report","year":"2008"},{"key":"10.1016\/j.reuma.2015.06.004_bib0525","series-title":"International Nonproprietary Names (INN) for Biological and Biotechnological Substances","year":"2012"},{"key":"10.1016\/j.reuma.2015.06.004_bib0530","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-9255-8-21","article-title":"Tyrosine kinases in rheumatoid arthritis","volume":"8","author":"Okamoto","year":"2011","journal-title":"J Inflamm (Lond)."},{"key":"10.1016\/j.reuma.2015.06.004_bib0535","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/jpet.109.158329","article-title":"Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation","volume":"331","author":"Hope","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-9255-11-14","article-title":"Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6","volume":"11","author":"Hammaker","year":"2014","journal-title":"J Inflamm (Lond)."},{"key":"10.1016\/j.reuma.2015.06.004_bib0545","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/jpet.114.220251","article-title":"Anti-inflammatory effects and joint protection in collagen-induced arthritis after treatment with IQ-1S, a selective c-Jun N-terminal kinase inhibitor","volume":"353","author":"Schepetkin","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0550","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gut.2009.179994","article-title":"A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease","volume":"59","author":"Dotan","year":"2010","journal-title":"Gut."},{"key":"10.1016\/j.reuma.2015.06.004_bib0555","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cgh.2005.11.013","article-title":"Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A randomized, double-blind, placebo-controlled trial","volume":"4","author":"Schreiber","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0560","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4110\/in.2013.13.6.283","article-title":"BIRB 796 has distinctive anti-inflammatory effects on different cell types","volume":"13","author":"Ryoo","year":"2013","journal-title":"Immune Netw."},{"key":"10.1016\/j.reuma.2015.06.004_bib0565","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/BOR.0b013e3283378e6f","article-title":"Kinase inhibitors: A new approach to rheumatoid arthritis treatment","volume":"22","author":"Cohen","year":"2010","journal-title":"Curr Opin Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0570","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/art.24266","article-title":"Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis","volume":"60","author":"Cohen","year":"2009","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0575","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0580","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0585","first-page":"174","article-title":"Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases","volume":"12","author":"Bajpai","year":"2009","journal-title":"IDrugs."},{"key":"10.1016\/j.reuma.2015.06.004_bib0590","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0595","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/art.30114","article-title":"An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents","volume":"63","author":"Genovese","year":"2011","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0600","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bone.2013.11.025","article-title":"The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss","volume":"60","author":"Shinohara","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.reuma.2015.06.004_bib0605","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.reuma.2015.06.004_bib0610","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0615","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/jpet.111.181545","article-title":"Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic\/pharmacodynamic modeling: Relationships between inhibition of BTK phosphorylation and efficacy","volume":"338","author":"Liu","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0620","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.38047","article-title":"Suppression of glomerulonephritis in lupus-prone NZB\u00d7NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase","volume":"65","author":"Mina-Osorio","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.004_bib0625","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.114.221176","article-title":"VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease","volume":"353","author":"Mahajan","year":"2015","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0630","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0635","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","author":"Papp","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0640","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0645","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0650","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0655","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reuma.2015.06.004_bib0660","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0665","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.004_bib0670","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0675","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2365","article-title":"Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis","volume":"10","author":"Milici","year":"2008","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.reuma.2015.06.004_bib0680","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/rheumatology\/ket466","article-title":"Effects of tofacitinib on lymphocytes in rheumatoid arthritis: Relation to efficacy and infectious adverse events","volume":"53","author":"Sonomoto","year":"2014","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.reuma.2015.06.004_bib0685","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/art.24485","article-title":"Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies","volume":"60","author":"Damjanov","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2015.06.004_bib0690","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1021\/jm100540x","article-title":"Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38\u03b1 MAP kinase inhibitor for the treatment of inflammatory diseases","volume":"53","author":"Liu","year":"2010","journal-title":"J Med Chem."},{"key":"10.1016\/j.reuma.2015.06.004_bib0695","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3899\/jrheum.100602","article-title":"A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis","volume":"38","author":"Genovese","year":"2011","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0700","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0705","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of Filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.reuma.2015.06.004_bib0710","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24\u01c0weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2015.06.004_bib0715","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12876-015-0239-9","article-title":"Randomized trial of tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes","volume":"15","author":"Pan\u00e9s","year":"2015","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.reuma.2015.06.004_bib0720","first-page":"62113","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: A phase 3 randomised non-inferiority trial","author":"Bachelez","year":"2015","journal-title":"Lancet."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1500114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X1500114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T02:55:44Z","timestamp":1537412144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X1500114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1699258X1500114X"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2015.06.004","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Los inhibidores de las prote\u00ednas-cinasas en enfermedades autoinmunes e inflamatorias: presente y futuro de nuevas dianas terap\u00e9uticas","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}